Senator Blackburn Questions HHS Secretary on Overprescribing Stimulant Drugs to Children

Pharmaceutical Industry Concerns

• 💡 Revolving door issues between pharmaceutical companies and regulatory bodies like CDC, NIH, and FDA are highlighted as unseemly.
• ✅ The senator expresses appreciation for the commitment to ending conflicts of interest within these agencies.

Pharmacy and PBM Legislation

• 💊 The senator discusses her PBM Act, which aims to keep rural pharmacies open and prevent PBMs from profiting excessively.
• 🤝 The Secretary confirms his commitment to working with senators to pass PBM legislation.

Interoperability and Digital Health

• 💻 A new interoperability framework announced by HHS is discussed, aiming to improve data sharing principles for digital health.
• 📜 The senator seeks clarity on how this new framework aligns with existing federal policies, emphasizing the need for a single national policy on interoperability.
• ✍️ The Secretary requests specific written details on the pathway for aligning these frameworks to ensure data benefits.

Overprescribing Stimulant Drugs to Children

• ⚠️ Concerns are raised about the overprescribing of stimulant drugs and antidepressants to children, with one in five children reportedly on these medications.
• 🔬 The Secretary acknowledges that long-term impacts are not well understood due to perceived inaction by NIH and CDC, stating that extensive studies are now underway.
• 📢 The goal of these studies is to warn parents and compel companies to label products accurately regarding long-term effects, including potential links to suicide.
• 🩹 The Secretary vows to address what he calls malpractice at these agencies regarding the lack of data on these drugs' impacts.